Heart-related mortality in men on ADT: a current perspective

A newly published study in BJU International suggests (unsurprisingly) that androgen deprivation therapy (ADT) is associated with an increased risk of death among men with such cardiovascular conditions as congestive heart failure or prior heart attacks. … READ MORE …

The PrKT03 trial of radiation + immunotherapy for localized prostate cancer

Back in September 2011, a company called Advantagene initiated a randomized, placebo-controlled, Phase III clinical trial (the PrKT01 trial) of an immunotherapeutic agent known as AdV-tk, together with with standard external beam radiation therapy, in highly-defined patients with newly diagnosed, localized prostate cancer. … READ MORE …

Who have you been spending intimate time with?

A paper just published in Cancer Epidemiology makes some striking claims about prostate cancer and sexual behavior that are likely to need to be thoroughly validated. … READ MORE …

CTFPHC rejects widespread screening for risk of prostate cancer

The Canadian Task Force on Preventive Health Care (CTFPHC) has just issued a guidance document that is not going to make most prostate cancer survivors very happy (either in Canada or elsewhere). … READ MORE …

Cancer drugs that don’t extend survival

An article by John Fauber in this Sunday’s issue of the Milwaukee Journal-Sentinel has been receiving a lot of attention in the oncology news over the past 48 hours. The title of this article is “FDA approves cancer drugs without proof they’re extending lives.” … READ MORE …

Expansion of indication for enzalutamide recommended in Europe

Late last week the Committee for Medicinal Products for Human Use (CHMP) in Europe recommended expansion of the marketing authorization for enzalutamide within member states of the European Union. … READ MORE …

An update on the shortage of radium-223 (Xofigo)

On October 21, here in the USA, Bayer HealthCare Pharmaceuticals issued a Dear Healthcare Professional letter to medical professionals indicating that the company still does not know when it is likely to be able to start to re-supply this radiopharmaceutical agent for the treatment of late-stage prostate cancer. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,157 other followers